title: Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.
abstract: Dopamine (DA) D(3) receptor antagonism might play a significant role in different therapeutic areas. A high number of preclinical studies on DA D(3) receptor antagonists have shown efficacy in animal models of Parkinson's disease, schizophrenia and drug dependence. This Review covers the activities of medicinal chemists in this field over the last ten years towards the identification of truly selective compounds. Both primary and patent literature is reviewed here. Since the original discoveries, a clear trend towards the optimization of the developability properties of the new scaffold has clearly emerged with time, from both academic and industrial researchers. Examples of advanced leads from academia and industry are described. The latest potential therapeutic applications are reported too.
authors.affiliation: Aptuit (Verona) s.r.l., Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy. fabrizio.micheli@aptuit.com
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Micheli
mesh_terms: D000818:Animals; D053961:Azabicyclo Compounds / Q000737:chemistry / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical; D018492:Dopamine Antagonists / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D010879:Piperazines / Q000737:chemistry / Q000493:pharmacokinetics; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014230:Triazoles / Q000737:chemistry / Q000493:pharmacokinetics
chemical_list: D053961:Azabicyclo Compounds; D018492:Dopamine Antagonists; D010879:Piperazines; D050637:Receptors, Dopamine D3; D014230:Triazoles